Fewer than a tenth of individuals eligible to benefit from GLP-1 drugs including Wegovy can access them, warns the World Health Organization as it releases its first recommendations on the medications.
Given over a billion people worldwide currently obese, it is advocating for increased and just availability to these injectable treatments.
According to forecasts, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"Our latest guidelines affirms that obesity is a lifelong illness that can be treated with comprehensive and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are key obstacles to widespread availability to the jabs that can assist patients in reducing substantial body mass, says the organization.
Skinny Jab Supply Crisis
Even under the current most optimistic outlook, the supply of such drugs could only cover about 100 million people – under 10% of those who need them, as stated by the WHO.
The guideline urges nations and manufacturers to widen access, by measures like voluntary licensing.
A patent on a key compound – the main ingredient of Novo Nordisk's Wegovy – is set to lapse in several nations in 2026.
The Way Weight-Loss Jabs Work
GLP-1 drugs replicate a biological compound to delay gastric emptying, suppress the appetite and enhance feelings of fullness so users eat less.
Patients commonly see weight reduction after several weeks of commencing the regular doses.
Studies points to patients may put most of the weight back on after a year of discontinuing the medication, because their typical hunger return.
To be overweight or obese elevates your chance for contracting diseases, like type 2 diabetes, heart disease, brain attack, and specific malignancies.
Obesity concerns individuals in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, per the WHO.
